Core Insights - Renaissance Investment Management's Q3 2025 "International Small Cap Equity Strategy" investor letter indicates that international equities have achieved positive returns for three consecutive quarters, on track for their best year since 2017 [1] - The portfolio outperformed its benchmark during the quarter, showcasing strong relative performance [1] Company Analysis: Nomad Foods Limited (NYSE:NOMD) - Nomad Foods Limited is a food company specializing in frozen food products, with a market capitalization of $1.854 billion as of December 10, 2025 [2] - The stock experienced a one-month return of -1.23% and a significant decline of 30.44% over the past 52 weeks [2] - The company was identified as the largest detractor from performance in the portfolio due to weaker-than-expected revenue attributed to unusually warm weather affecting frozen food sales [3] - Rising input costs are anticipated, with recovery expected only after price adjustments in 2026 [3] Hedge Fund Interest - Nomad Foods Limited was held by 32 hedge fund portfolios at the end of Q3 2025, an increase from 24 in the previous quarter [4] - Despite its potential, the company is not considered among the 30 most popular stocks among hedge funds, with some analysts suggesting that certain AI stocks present greater upside potential and lower downside risk [4]

Group 1 - Eli Lilly's drug Mounjaro will be added to China's national health insurance program starting January 1, which could increase competitive pressure on rival companies [2][4] - Inclusion in the national reimbursement list enhances accessibility of Mounjaro to China's 1.4 billion population, although lower prices may offset some revenue gains despite increased sales volume [3] - Mounjaro, a once-weekly injectable therapy, was launched in China in January this year, following the introduction of a similar treatment, Ozempic, from Novo Nordisk [4] Group 2 - Eli Lilly is recognized as a major American pharmaceutical company focused on developing medicines for serious conditions [5] - While Eli Lilly shows potential as an investment, certain AI stocks are suggested to offer greater upside potential and less downside risk [5]

Core Viewpoint - Colgate-Palmolive Company (NYSE:CL) is recognized as a long-term investment opportunity despite facing challenges in the current market environment [2][3]. Group 1: Company Performance and Outlook - RBC Capital upgraded Colgate-Palmolive's rating to Outperform from Sector Perform, maintaining a price target of $88, indicating confidence in the company's long-term growth potential despite recent pressures from slower global category growth [2]. - The CEO highlighted a volatile operating environment influenced by consumer uncertainty, tariffs, geopolitical issues, and high cost inflation, which have impacted sales and profitability [3]. - Colgate-Palmolive updated its organic sales growth outlook to approximately 1.2% for 2025, factoring in a 70 basis point impact from exiting private label products [4]. Group 2: Strategic Focus and Market Position - The company remains committed to its 2030 Strategy, emphasizing its strong brand portfolio in growing categories and significant market share, particularly in emerging markets [3]. - Colgate-Palmolive has a highly efficient global supply chain that supports its demand, positioning the company favorably for future growth [3]. - The company has a long-standing history of reliability as a dividend payer, having increased its dividends for 62 consecutive years, which adds to its attractiveness as an investment [4].

Core Insights - Arthur J. Gallagher & Co. (NYSE:AJG) is recognized as one of the 15 Best Stocks to Buy for the Long Term [1] - Wells Fargo analyst Elyse Greenspan has reduced the price target for AJG from $362 to $344 while maintaining an Overweight rating, citing expected pressure on margins for Q4 2025 [2] - The company has been actively acquiring firms, including the recent purchase of UK-based First Actuarial and Tompkins Insurance Agencies in New York [3] Financial Performance - AJG reported a strong third quarter with a 20% total revenue growth, marking its 19th consecutive quarter of double-digit growth [4] - The incremental revenue from acquisitions in Q3 was $450 million, with six acquisitions closed that are expected to generate over $3 billion in annualized revenue [4] Company Overview - Arthur J. Gallagher & Co. is an American insurance brokerage, risk management, and consulting services firm operating in approximately 130 countries globally [5]

Group 1 - Consolidated Edison, Inc. (NYSE:ED) is recognized as one of the 11 Energy Stocks to consider for a retirement portfolio [1] - The company operates one of the largest energy delivery systems globally, serving 10 million customers in New York City and Westchester County [2] - Consolidated Edison has agreed to divest its approximately 6.6% interest in the Mountain Valley Pipeline for $357.5 million, with the transaction expected to close in the first half of 2026 [3] Group 2 - The proceeds from the divestment will be used to partially offset the company's common equity needs for the upcoming year and for general corporate purposes [3] - On November 21, Consolidated Edison faced pressure from President Trump and New York City Mayor-elect Zohran Mamdani to reduce its rates, citing that lower fuel prices have not been reflected in the utility's rates [4]

Group 1 - Duke Energy Corporation (NYSE:DUK) is involved in the distribution of natural gas and energy-related services, operating a diverse mix of regulated power plants including hydro, coal, nuclear, natural gas, solar, and battery storage [2][3] - The company has proposed a rate hike of approximately 15% over the next two years, which would result in residential customers paying an additional $20 to $30 per month by 2028 [3] - North Carolina leaders, including Attorney General Jeff Jackson and Governor Josh Stein, have opposed the proposed rate hikes, arguing that they are too high and come at a time when families are struggling financially [4] Group 2 - The North Carolina Utilities Commission is expected to make a decision on the proposed rate hike in late 2026 after public hearings [4]

Core Insights - Citi Trends, Inc. (NASDAQ:CTRN) is recognized as one of the best micro-cap stocks to invest in according to analysts [1] Financial Performance - For the third quarter, Citi Trends reported revenue exceeding $197 million, reflecting a 10% increase compared to the same period last year and surpassing market expectations by nearly $10 million [2] - The company anticipates fourth-quarter comparable store sales to rise in the high single digits, with gross margin projected to be between 40% and 41% [2] Analyst Ratings - DA Davidson analyst Michael Baker raised the price target for Citi Trends stock from $43 to $52 while maintaining a Buy rating [3] - Baker noted that the company is experiencing a merchandise-driven turnaround, with comparable sales momentum continuing into the holiday season [3] - The analyst highlighted that the inventory is fresh, differentiated, and on-trend, contributing to above-average incremental margins due to a high fixed cost structure [3] Company Overview - Citi Trends operates as a value retailer specializing in fashion apparel, accessories, and home goods [4]

Core Insights - Omeros Corporation has secured a significant deal with Novo Nordisk valued at approximately $2.1 billion for its phase 2 asset, zaltenibart, aimed at treating rare blood and kidney disorders [2] - Analysts on Wall Street are optimistic about Omeros, with HC Wainwright assigning a Buy rating and a price target of $9 for the company's shares [3] Company Overview - Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics, particularly for orphan indications targeting immunologic diseases [4] Product Pipeline - The lead product candidate of Omeros is Narsoplimab, which is being developed for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy [3] - Omeros is also developing OMS1029, which has successfully completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 and lectin pathway disorders [3]

Core Insights - Immutep Limited (NASDAQ:IMMP) is recognized as a promising micro-cap stock by analysts [1] - The company reported positive results from clinical trials for its drug candidate eftilagimod alpha (efti), showing significant efficacy in treating soft tissue sarcoma and a high overall survival rate for lung cancer patients [2] - A Phase III trial for efti as a first-line treatment for advanced non-small cell lung cancer has successfully enrolled over 170 patients, surpassing the necessary amount for futility analysis [3] Company Overview - Immutep Limited is a biotechnology firm focused on developing novel immunotherapies related to Lymphocyte Activation Gene-3 for cancer and autoimmune diseases, based in Australia [4]

We recently published Small But Savage: 10 Stocks Delivering Outsized Gains. T1 Energy Inc. (NYSE:TE) is one of the best performers on Tuesday. T1 Energy extended its winning streak to a fourth straight day on Tuesday to hit a new two-year high as investors took path from an investment firm’s bullish rating and price target for the stock. At intra-day trading, the stock surged to its highest price of $7.04 before trimming gains to finish the day just up by 11.79 percent at $6.73 apiece. T1 Energy (TE) J ...